10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

AstraZeneca1,114 enrolled

Overview

10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.

Study Type

OBSERVATIONAL

Enrollment

1,114

Conditions

Breast Cancer

Eligibility

Sex: FEMALEMin age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Early Breast Cancer patients * Postmenopausal Status * patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months Exclusion Criteria: * Advanced Breast Cancer patients(stage iii, iv) * Patients who are hard to be analysed by limitation of chart record according to investigators discretion * patients who already have been registered in this study

Locations (27)

Research Site

Cheonan, Chungcheongnam-do, South Korea

Research Site

Outcomes

Primary Outcomes

The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment.

Time frame: 1 visit

Secondary Outcomes

To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer

Time frame: 1 Visit

To analyse CHD management patterns according to defined 10-year CHD risk categories

Time frame: 1 Visit

To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk

Time frame: 1 Visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.